Trial Profile

Phase I, open label, single dose Safety and Pharmacokinetics study of SYM-1219 (Secnidazole) in Healthy Female Volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Secnidazole (Primary)
Indications Bacterial vaginosis
Focus Pharmacokinetics; Therapeutic Use
Sponsors Symbiomix Therapeutics

Most Recent Events

07 Nov 2016 According to a Symbiomix Therapeutics media release, data will be presented at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition.
21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
04 Mar 2015 According to a Symbiomix Therapeutics media release, results will be presented at the annual meeting of the American Society of Clinical Pharmacology and Therapeutics.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com